Sickle Cell Crisis
15
1
1
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
6.7%
1 terminated out of 15 trials
90.0%
+3.5% vs benchmark
33%
5 trials in Phase 3/4
33%
3 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (15)
Optimal Timing of Ketamine Initiation for SCD Pain
Ketamine for Acute Painful Crisis in Sickle Cell Disease Patients
Ketorolac for Acute Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease
Virtual Reality as an Adjuvant Therapy for Sickle Cell Vaso-Occlusive Crisis in the Pediatric Emergency Department
Lidocaine Intravenous in the Emergency Department For Sickle Cell Crisis
Sickle Cell Improvement: Enhancing Care in the Emergency Department
Evaluation of the Efficacy of Intra-nasal Sufentanil for Analgesia of Vaso-occlusive Crisis in Sickle-cell Adults.
Mindfulness and Yoga Therapy for Acute Pain in Sickle Cell Disease
Transillumination Device for Peripheral Intravenous Placement in Patients With Sickle Cell Disease (PERFID)
Low Dose Ketamine and Acute Pain Crisis
Music Therapy: Sickle Cell and Pain Crisis
The Use of Warmed Saline in Vaso-occlusive Episodes
A Comprehensive Care Plan for Pediatric Patients With Vaso-Occlusive Crises
Low-dose Ketamine vs Morphine for Vaso-occlusive Crisis in Sicklers
Intermittent Preventive Treatment for Malaria in Patient With Sickle Cell Disease